Tag: cases

DUBAI, UAE, June 16, 2026 /PRNewswire/ -- Cloudzy, the independent cloud and VPS hosting provider serving more than 122,000 businesses and entrepreneurs worldwide since...

YY Group completes US$20 million ATM Program, raising approximately US$19.1 million net proceeds for AI, robotics and IFM initiatives.

Complementary upstream and downstream capabilities to enhance integration and enable the combined company to better create value across cycles, products and regions $400+ million...

NEW YORK, June 16, 2026 /PRNewswire/ -- ...

162 million 5G subscriptions added during the first quarter of 2026, bringing the total to 3.1 billionThe number of commercial differentiated connectivity service offerings...

BEIJING, June 16, 2026 /PRNewswire/ -- Reading the news about the just concluded Second World Conference of Classics in Athens reminds me of my...

Handcrafted in San Francisco, the Gramercy Leather Sling offers a full-grain leather alternative to the technical fabric crossbody bags that dominate compact everyday carry....

REYKJAVIK, Iceland , June 16, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the pricing of its previously announced underwritten public offering (the “Offering”) of 22,666,667 of its ordinary shares at an offering price of $3.75 per share. All ordinary shares to be sold in the Offering will be offered by Alvotech. The Offering is expected to close on or about June 17, 2026, subject to satisfaction of customary closing conditions. The Company has also granted the underwriters a 30-day option to purchase up to an additional 3,400,000 ordinary shares at the public offering price, less underwriting discounts and commissions. Before deducting the underwriting discounts and commissions and offering expenses, the Company expects to receive total gross proceeds of approximately $85 million from the Offering, or approximately $98 million if the underwriters exercise in full their option to purchase additional shares.

NEW YORK, June 15, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Regencell Bioscience Holdings Limited (NASDAQ: RGC) between October 28, 2024 and October 31, 2025, inclusive (the “Class Period”), of the important June 23, 2026 lead plaintiff deadline.

DERM Zero is a world-first - using Class III regulated medical device1 technology to deliver autonomous clinical grade skin cancer assessments from a standard...

MRD has scaled into a profitable, category-leading MRD diagnostics business, while Immune Medicine has built a differentiated discovery platform powered by proprietary immune data and AI

MRD has scaled into a profitable, category-leading MRD diagnostics business, while Immune Medicine has built a differentiated discovery platform powered by proprietary immune data and AI

NEW YORK, June 15, 2026 /PRNewswire/ -- During a moment when AI is rapidly moving from dashboards into decision-making systems, a new partnership between Allora...